Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yosi s who wrote (843)	5/21/1998 9:58:00 AM
From: Ariella	Read Replies (1) of 1491

Pharmos Corporation's Dexanabinol May Provide Treatment for Ulcerative Colitis; Study Suggests Additional Application for Drug NEW ORLEANS, May 21 /PRNewswire/ -- Dr. Kevin McHugh of McMaster University and Coordinator of the Canadian IBD Research Network presented new findings demonstrating significant efficacy for Pharmos Corporation's (Nasdaq: PARS - news) dexanabinol (HU-211) in an animal model of ulcerative colitis. The new data were presented at the American Gastroenterology Association conference held this week in New Orleans. Dr. McHugh commented that his findings could be significant for the treatment of both inflammatory bowel disease (IBD) and AIDS wasting syndrome. biz.yahoo.com Big NEWS, yes????? Ariella

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next